Read our Recent Headlines


February 26th Biotech Update

First, I apologize for the emails last night. We all received them as well and no one understands why quite yet. We are looking into it right now and hopefully.

February 25 Biotech Update

Today will be interesting for the markets. As I noted, the market has trained most to buy the dips and big sell-offs are followed by new highs. The gap up.

February 24th Biotech Update

As I have been saying COVID risk will re-enter the market when (if) it expands outside of China and we now have 4 potential non-China epidemics in the works with.

February 21st Biotech Update

I am back and the sector has barely changed. I do feel, however, that we are closer to a move lower than before. The market seems to be revising both.

February 19th Biotech Update

The curious case of the flat market continues. At this point, I would call it a clear trend (with the trend being sideways). I know I have been waiting for.

February 18th Biotech Update

What an odd market. Fundamentally it should be struggling. It was overbought and PE stretched and we are now starting to see earnings warnings from the corona virus and yet.

February 14th Biotech Update

You remember how I believed that the sector was at a decision point and was unlikely to hang out close to the recent highs without breaking out or breaking down?.

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!